Phospholipid Nanoparticle NSAID Encapsulation for Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NSAIDs have low solubility and bioavailability, leading to high doses required for therapeutic effects, which can cause adverse effects such as gastrointestinal issues and increased cardiovascular risk, and they struggle to target inflammatory pathways effectively, especially for long-term therapy.
Innovation Solution
Phospholipid nanoparticle compositions encapsulating NSAIDs are developed using an unfired sequential process, increasing bioavailability 2- to 10-fold and reducing doses needed for therapeutic effects, while minimizing pathogenic effects by using phospholipids to form stable nanoparticles that can bypass biological barriers and deliver NSAIDs directly to target sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard NSAID pills and capsules are used, then the therapeutic effect is achieved, but the bioavailability is low requiring high doses which cause adverse effects
Solution Approach 1:
The patent changes the physical and chemical parameters of NSAIDs by encapsulating them in phospholipid nanoparticles, transforming them from poorly soluble crystalline forms into stable nanoscale dispersions with enhanced solubility and bioavailability, thereby reducing the required dose while maintaining therapeutic effect
Solution Approach 2:
The patent creates a composite material system consisting of NSAIDs encapsulated within phospholipid nanoparticle structures, combining the therapeutic properties of NSAIDs with the biocompatibility and solubility-enhancing properties of phospholipids to achieve both efficacy and safety
2Reliability
If high doses of NSAIDs are used to overcome low solubility, then therapeutic effect is improved, but gastrointestinal issues and cardiovascular risk increase
Solution Approach 1:
The patent changes the dissolution rate and solubility parameters of NSAIDs through nanoparticle encapsulation, enabling complete dissolution at lower concentrations before absorption, which prevents gastrointestinal irritation while maintaining adequate plasma levels for therapeutic effect
Solution Approach 2:
The phospholipid nanoparticle acts as an intermediary carrier that protects the NSAID during gastrointestinal transit, controlling its release and dissolution in a manner that prevents direct contact with gastric mucosa, thereby eliminating gastrointestinal side effects while ensuring adequate drug delivery
3Reliability
If NSAIDs are administered to target inflammatory pathways, then anti-inflammatory activity is achieved, but bioavailability limits effectiveness
Solution Approach 1:
The patent changes the solubility and dissolution rate parameters of NSAIDs by formulating them as phospholipid nanoparticles, increasing their aqueous solubility and dissolution rate by several-fold, which directly improves bioavailability and ensures adequate drug concentrations reach the inflammatory targets
Solution Approach 2:
The phospholipid nanoparticle formulation provides multiple functions simultaneously: it enhances solubility, controls dissolution rate, protects the drug from degradation, and facilitates absorption, thereby overcoming multiple limitations of conventional NSAID administration with a single delivery system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables safe, long-term, and more effective NSAID therapy with reduced side effects, enhancing therapeutic activity and bioavailability, allowing for lower doses to achieve the same therapeutic effects as standard NSAID pills and capsules, while effectively targeting inflammatory disorders and global inflammation.
Implementation Method 1
yielding an increase NSAID transport across hydrophobic mucosa
Implementation Method 2
where the phospholipids in the nanoparticle structure reduce or eliminate pathogenic effects of NSAIDs
Data Source
AI summary
Novel process and products thereby emplace NSAIDS within nanodelivery vehicles for various indications in mammals, including humans.